Table 3.
Clinical characteristics of 85 NPHP1 patients with subsequent eGFR values on and off ACEI treatment.
| Patient characteristics | ACEI− | ACEI+ |
|---|---|---|
| Number of patients (n) | 62 | 23 |
| DeltaGFR values (n) | 125 | 47 |
| Male/female | 33/29 | 12/11 |
| Age at study entry (yrs) | 10.2 ± 3.7 (2.4–20.8) | 13.9 ± 7.9 (4.4–33.4) |
| CKD stage, n (%) | ||
| CKD1 | 3 (4) | 2 (9) |
| CKD2 | 7 (10) | 1 (4) |
| CKD3 | 26 (38) | 11 (48) |
| CKD4 | 23 (34) | 10 (43) |
| CKD5 | 9 (13) | 3 (13) |
| Absolute GFR loss/yr (ml/min per 1.73 m2cBSA) | 5.2 ± 0.6 | 7.2 ± 0.4 |
ACEI, angiotensin-converting enzyme inhibitor; BSA, body surface area; CKD, chronic kidney disease; GFR, glomerular filtration rate.
DeltaGFR values were determined for individuals with at least 2 subsequent eGFR values in intervals of minimum 3 months. This way we were able to generate 125 deltaGFR values from 62 patients without and 47 deltaGFR values from 23 patients with the influence of ACEI treatment.